Introduction
============

Pulmonary rehabilitation is a suitable treatment for COPD since it reduces symptoms, decreases disability, increases participation in physical and social activities and improves the overall health-related quality of life (HRQoL) in patients with chronic respiratory disease.[@b1-copd-12-2059]--[@b3-copd-12-2059] Nevertheless, pulmonary rehabilitation is not often prescribed and patients often do not follow the prescribed exercise training in everyday life.[@b4-copd-12-2059],[@b5-copd-12-2059] In addition to the well-known clinical comorbidities, cognitive impairment, anxiety, depression, and low adherence to clinical prescriptions are frequent and may affect pulmonary rehabilitation delivery.[@b3-copd-12-2059],[@b6-copd-12-2059]--[@b8-copd-12-2059] Moreover, self-efficacy on exercise could play an important role in patients' pulmonary rehabilitation attendance and in improving functional outcomes.[@b9-copd-12-2059]

Attention and executive dysfunctions are frequent features of mild cognitive impairment (MCI) in COPD.[@b10-copd-12-2059],[@b11-copd-12-2059] Furthermore, patients with COPD report high levels of anxiety and depression, which are associated with disease severity and are related to psychosocial constructs, such as poor quality of life, living alone, female sex, smoking and low socioeconomic status.[@b12-copd-12-2059]--[@b14-copd-12-2059] Anxiety and depression identified in subjects with stable COPD were significantly associated with increased overall length of event-based exacerbations in patients with at least one exacerbation.[@b15-copd-12-2059] Moreover, depression is a risk factor for increased COPD exacerbations, hospitalizations and mortality.[@b16-copd-12-2059]

In COPD management, good pharmacological adherence decreases the frequency and severity of exacerbations, improves overall HRQoL and prolongs survival.[@b17-copd-12-2059] Unfortunately, half of COPD patients abandon the treatment with inhaled medication during the first year of therapy.[@b18-copd-12-2059] Furthermore, even if prescribed, less than half of the patients use oxygen therapy and only 25% of patients use oxygen therapy during activities outside their house.[@b19-copd-12-2059]

Accurate measurement of medication adherence is important in terms of both research and clinical practice. There are many methods to assess adherence; direct (objective physiological/biochemical analysis) or indirect ones (objective monitoring of medication usage or patient's self-report). Each method has advantages and disadvantages, but no single method is sufficiently reliable and accurate; thus, a combination of assessment methods may be preferred in order to increase validity and reliability of the information collected.[@b20-copd-12-2059] Moreover, as described in the literature, most of the tools used to assess adherence and the interventions to enhance medication adherence do not focus on behavioral prescriptions, but focus mainly on taking or not taking drugs.[@b7-copd-12-2059]

To the best of our knowledge, there is a lack of scientific literature describing simultaneously the associations between depressive symptoms, anxiety, MCI and self-reported adherence in COPD patients.

The aims of this study are: 1) to describe a COPD population in a rehabilitative setting as regards their depressive symptoms, anxiety, MCI and self-reported pharmacological and nonpharmacological adherence; 2) to compare the COPD sample MCI scores with normative data; 3) to analyze the relationships between self-reported adherence to behavioral prescriptions and clinical, psychological, neuropsychological variables; and 4) to investigate which factors might predict adherence to exercise at home following medical advice.

Methods
=======

Subjects
--------

For this multicenter observational cross-sectional study, all patients with COPD consecutively admitted to the Clinical Scientific Institutes Maugeri, IRCCS -- Department of Pulmonary Rehabilitation, Montescano (PV), Camaldoli (MI) and Tradate (VA) -- from September 2013 to March 2014 were considered eligible. Patients were diagnosed according to Global initiative for chronic Obstructive Lung Disease (GOLD) criteria (Stage II--IV, C--D); they were in clinically stable condition (no exacerbations in the last 3 months) with optimized stable pharmacological therapy (inhalation therapy with long-acting anticholinergic and/or β2-agonists, inhaled corticosteroids when needed).

The exclusion criteria were severe medical conditions that did not allow assessment (severe chronic inflammatory diseases, chronic heart failure, neoplastic diseases, acute respiratory diseases), no Italian education or relapse into illiteracy, severe visual-perceptive deficits, low subjective motivation or refusal to undergo the evaluation, severe psychiatric disorders (by medical psychiatric evaluation) and severe cognitive deterioration (Mini Mental State Examination \[MMSE\] score ≤18.3).[@b21-copd-12-2059]

All the patients signed written informed consent form for this study. The study was approved by our institutional Review Board and Central Ethical Committee belonging to the ICS Maugeri SpA SB (CEC) (approval number: CEC N.927, 27/06/2013).

Procedure
---------

All patients were admitted to an inpatient comprehensive rehabilitation program: educational sessions, exercise training (cycloergometer and/or treadmill, arms ergometer), respiration against resistance, calisthenics, psychological counseling, and metabolic evaluation with a personalized diet when needed.

During the first week of admission, all enrolled patients underwent an individual psychological and neuropsychological assessment.

The psychological and neuropsychological assessment included the Hospital Anxiety and Depression Scale (HADS),[@b22-copd-12-2059] the 30-point Geriatric Depression Scale (GDS),[@b23-copd-12-2059] the Beck Depression Inventory (BDI-II),[@b24-copd-12-2059] the Morisky, Green, and Levine Adherence Scale (MGL Adherence Scale),[@b25-copd-12-2059] the Adherence Schedule in Chronic Obstructive Lung Disease -- Revised (ASiCOLD-R),[@b26-copd-12-2059] the MMSE[@b21-copd-12-2059] and the Montreal Cognitive Assessment (MoCA).[@b27-copd-12-2059]

The psychological and neuropsychological assessment was divided in two sessions: 1) MMSE and psychological test, and 2) MoCA, which was administered a few days later in order to avoid an interference effect.

Trained psychologists evaluated the patients according to standardized administration and scoring procedures. The patients were supported throughout the testing period to maintain motivation and to elicit the optimal level of performance; a break was always allowed if necessary.

Instruments
-----------

MMSE was adopted to screen for cognitive impairment according to the Measso et al distribution; at a 0.95≤α≤0.99 confidence level, the score range of 18.3--23.8 could be associated with moderate, and no severe, cognitive impairment, with a high probability that those scores reflected a diminished performance for reasons other than aging or poor education.[@b21-copd-12-2059]

The MoCA was used as a screening instrument for MCI by assessing memory, language, executive functions, visuospatial skills, calculation, abstraction, attention, concentration and orientation. The MoCA is freely accessible for clinical and educational purposes; it is available in 36 languages, including Italian ([www.mocatest.org](http://www.mocatest.org)). Recent normative data can be used to assess MCI with the equivalent scores (ES) classification, with more precision than the standard cutoff (≤26);[@b9-copd-12-2059],[@b27-copd-12-2059] for normative data we referred to the Conti et al classification, in line with the distribution of our patient sample.[@b28-copd-12-2059] In this study, MoCA scores were categorized as Yes MCI (ES 0) and No MCI (ES 1--4) according to the ES, where 0 corresponds to an inferentially controlled judgment of being below the norm; 4 is equal to or better than the 50th percentile; and 1, 2 and 3 are obtained by dividing into three equal parts the area of the distribution between 0 and 4 are considered as not impaired (37). Therefore, Yes MCI identified patients with an MCI stemming from MoCA data.[@b28-copd-12-2059]

The level of anxiety was evaluated by HADS-A,[@b29-copd-12-2059] specific for hospitalized patients. HADS-D (depressive symtoms) was not considered. BDI-II for younger patients (\<65 years) and GDS for older patients (≥65 years) were adopted due to their excellent reliability compared to HADS-D and due to items' content and number.[@b30-copd-12-2059] The BDI-II patients' scores were corrected according to sex and divided into percentile points. Depressive and anxious symptoms scores were also classified into low (none or mild) and moderate/severe (moderate or severe).

Self-reported adherence to medical plans was assessed by MGL Adherence Scale and ASiCOLD-R. The well-known MGL Adherence Scale was adopted for evaluating pharmacological adherence and the total score was considered (range 0--4).[@b25-copd-12-2059] The ASiCOLD-R (Appendix A) belongs to a wider group of schedules aimed at assessing the cognitive, relational and behavioral antecedents of self-reported adherence to treatment in different chronic diseases (chronic heart failure, cardiovascular heart disease, asthma, COPD). The ASiCOLD-R investigates a patient's disease perception such as disease acceptance (DA), disease limitations acceptance (DLA), family/social support and self-efficacy in disease management in relation to pharmacological and nonpharmacological prescriptions (eating, smoking, exercise, long-term oxygen therapy \[LTOT\]) (see Appendix A). ASiCOLD-R answers were classified into low (not at all, a little) and moderate/high (enough/much/very much) disease perception and self-efficacy in following medical prescriptions.[@b26-copd-12-2059]

Statistical analysis
--------------------

Descriptive statistics are reported as mean ± SD for continuous variables and as n (frequency percentage) for discrete variables.

Differences between groups for continuous variables were assessed by Student's *t*-test for unpaired samples or by Mann--Whitney test when appropriate. Comparisons of categorical variables were carried out by chi-square test or Fisher's exact test when appropriate.

To identify which factors were independent predictors of adherence to exercise prescriptions (dependent variable), we developed a multivariate predictive model (logistic regression) using the following candidate predictors: age, sex, DA, DLA, depression, anxiety, MCI and body mass index (BMI). To avoid overfitting, less predictive variables were eliminated by a backward elimination procedure at the significance level of 0.1.

All statistical tests were two-tailed, and statistical significance was set at *P*\<0.05. All analyses were carried out using the SAS/STAT statistical package, release 9.2 (SAS Institute Inc., Cary, NC, USA).

Results
=======

In our multicenter cross-sectional observational study, 117 inpatients affected by COPD, stage II--IV GOLD, were considered eligible, but 33 of them were excluded (n=4, clinical exacerbation during hospitalization; n=4, relapse into illiteracy; n=4, visual-perceptive deficits; n=16, low subjective motivation to undergo the evaluation, or refusal; n=5, severe psychiatric diseases). Eighty-four patients were included in the study.

[Tables 1](#t1-copd-12-2059){ref-type="table"} and [2](#t2-copd-12-2059){ref-type="table"} show the sociodemographic and clinical characteristics.

[Table 3](#t3-copd-12-2059){ref-type="table"} illustrates the psychological and neuropsychological assessment scores (depression, anxiety, cognitive deterioration and MCI). Regarding the cognitive functions, 3.6% of COPD patients were found to be impaired as per the MMSE. From the MoCA test, COPD patients were more likely to have an MCI in comparison with normative cognitive data (9.5% vs 2.6%, *P*=0.0006).[@b28-copd-12-2059]

The MGL Adherence Scale total score highlighted that only 16.7% of COPD patients reported low pharmacological adherence. [Table 4](#t4-copd-12-2059){ref-type="table"} shows the ASiCOLD-R score distribution relating to disease perception and self-efficacy on nonpharmacological clinical prescriptions.

By comparing sociodemographic variables with ASiCOLD-R, depression and anxiety scores, no significant relations were found. The ASiCOLD-R items that refer to perceived social support, following dietary prescription, exercising following medical advice and avoiding smoking did not show significant associations with depression, anxiety and MCI. There was no significant relationships between ASi-COLD-R, depression, anxiety scores and MCI when compared with months of illness and spirometric parameters (forced expiratory volume in 1 second \[FEV~1~\], FEV~1~% predicted, forced vital capacity \[FVC\], FVC% predicted, FEV~1~/FVC).

DA was significantly related to depressive symptoms (*P*=0.0015), anxiety (*P*=0.03) and MCI (*P*=0.01); patients with higher DA reported lower depression and anxiety symptoms and were less likely to have cognitive impairment. DLA was proved to be significantly related to depressive symptoms (*P*=0.0004) and anxiety (*P*=0.02); patients with higher DLA reported lower depression and anxiety symptoms. Significantly lower depressive symptoms were reported by patients with a higher familial support and by patients referred for less frequent LTOT modifications (*P*=0.02, *P*=0.03 respectively). The 6-minute walking test (6MWT) was significantly related to DLA; patients with low DLA walked shorter distances than patients with moderate/high DLA (288.0±97.0 vs 354.0±122.0 minutes, *P*=0.031). Patients with low adherence to dietary prescriptions had a higher BMI than patients with moderate/high adherence to dietary prescriptions (28.6±6.2 vs 25.2±6.7 kg/m^2^, *P*=0.05). Patients with low adherence to exercise following medical advice had a higher BMI than patients with moderate/high adherence to exercise, following medical advice (28.6±7.2 vs 23.3±5.0 kg/m^2^, *P*=0.002). Moreover, moderate/severely depressed patients had a more severe COPD, in terms of GOLD (3.1±0.7 vs 2.8±0.9, *P*=0.05) and walked shorter distances in the 6MWT (285.0±103.0 vs 355.0±119.0 m, *P*=0.022) than patients with a low (none or mild) depression level. Lastly, patients with MCI reported more frequent depressive symptoms (*P*=0.0036) ([Figure 1](#f1-copd-12-2059){ref-type="fig"}).

Among the set of variables that were considered as potential predictors of adherence to exercise prescriptions (ie, age, sex, DA, DLA, depression, anxiety, MCI and BMI), only BMI, depression and anxiety were identified by the multivariate logistic regression analysis as significant and independent predictors of adherence to exercise prescriptions. In particular, higher BMI, a higher level of depression and less anxiety were associated with lower adherence (*P*=0.0004, odds ratio =0.796, 95% CI =0.701, 0.903; *P*=0.009, odds ratio =0.356, 95% CI =0.165, 0.770; and *P*=0.05, odds ratio =2.361, 95% CI =0.995, 5.627 respectively).

Discussion
==========

With respect to previous publications, our study adds an overview on several variables related to self-reported adherence on disease management at home in COPD patients, with particular attention to psychological/neuropsychological ones, such as MCI, depression, anxiety and DA/behavioral adaptation.

From a psychological point of view, less than half of our COPD patients report depression and anxiety, from mild to severe levels. Taking into account Maurer et al's questions about the accuracy of depression and anxiety screening instruments, in our work particular attention was paid to patients' selection, validation, specificity for age and clinical condition.[@b6-copd-12-2059],[@b31-copd-12-2059] We took the same care with MCI evaluation using two different and well-known screening tests. Our results confirmed that MoCA is more accurate than MMSE for screening MCI, probably due to the better ability of the former to detect executive functions compared to the latter.[@b9-copd-12-2059],[@b17-copd-12-2059],[@b32-copd-12-2059] Regarding adherence, our data are in line with international literature concerning both assessment procedure and results. Despite the well-known limits of adherence assessment by self-report tools, which may overestimate adherence,[@b20-copd-12-2059] between one-third and one half of our patients report difficulties in adhering to behavioral prescriptions, thus stressing the necessity to intervene specifically on these aspects. Regarding disease perception, one-third of our patients struggle with DA and adaptation as shown in previous studies.[@b33-copd-12-2059] On the other hand, most of them report that they live in a supportive environment in line with the WHO ICF model, which stresses the necessity to assess the environmental factors, both as barriers and as facilitators, when dealing with a chronic disease such as COPD.[@b34-copd-12-2059]

In order to compare MCI data with the Italian normative population, MoCA raw scores were adjusted according to different levels of age and education and transformed into ES, getting a more accurate screening cutoff than with MMSE.[@b9-copd-12-2059],[@b28-copd-12-2059],[@b32-copd-12-2059] In our sample, a significantly higher percentage of MCI was highlighted when adopting MoCA-ES compared to MMSE. Given the wide range variability of cognitive impairment described in COPD literature and the different cutoffs and assessment tools adopted,[@b10-copd-12-2059],[@b11-copd-12-2059] our data confirm the necessity to proceed with further studies on this topic. Lastly, MoCA data transformation in ES allowed focused and effective comparisons with other variables in our study.[@b9-copd-12-2059],[@b32-copd-12-2059]

Several features stand out when examining [Figure 1](#f1-copd-12-2059){ref-type="fig"}. The most relevant is the opportunity to view the patient as a whole, taking into account many different aspects of being ill; clinical variables, psychological/neuropsychological factors, disease perception and nonpharmacological adherence are all interrelated. The role of depression strongly emerged due to its significant relations with many of the variables considered, from clinical aspects (COPD severity and 6MWT) to nonpharmacological adherence (autonomous LTOT modifications), from disease perception (DA, DLA and family support) to mild cognitive deficits. BMI also had a significant relation to nonpharmacological adherence (exercising and following dietary prescriptions).

From a clinical psychological point of view, other observations may be made. The relations between DA, adaptation to behavioral limitations (DLA) and psychological, neuropsychological and functional (6MWT) factors point out the importance of intervening on subjective disease perception.[@b35-copd-12-2059]--[@b39-copd-12-2059] The higher the DA and adaptation, the lower the depression and anxiety and the better the levels of motor functionality and vice versa ([Figure 1](#f1-copd-12-2059){ref-type="fig"}).

Since MCI was not related to the clinical variables and behavioral prescriptions, but only to psychological aspects, we could make the following considerations: MCI seemed to be a factor in its own right in the clinical variables and, on the other hand, it relates to depression, coherent with data on COPD patients with initial signs of subjective cognitive complaints.[@b6-copd-12-2059],[@b10-copd-12-2059]

In our regression model, BMI, depression and anxiety independently predicted adherence to exercise prescriptions at home. The BMI role was expected, whereas the independent role of the psychological aspects in literature is described as indirect or mediated by other variables.[@b38-copd-12-2059]--[@b42-copd-12-2059] Given our sample size and the specific clinical characteristics of our population, this topic deserves further studies for its relevant clinical implications.

Our study has some strengths and limitations. The strong points are that it is a multicentric study, it provides the first Italian normative MoCA data on COPD patients, and it relates clinical and psychological/neuropsychological variables to adherence at home in everyday life. The limitations are that the evaluation carried out with inpatients who voluntarily attended rehabilitation departments does not allow us to apply our findings to the general population of COPD patients; our study has a high number of variables and evaluates adherence without objective tools; and small sample size does not allow addressing generalizable conclusions.

Implications for clinical practice
----------------------------------

Some clinical implications can be drawn from our data, which confirm what has been described in the literature regarding the factors linked to pulmonary rehabilitation.[@b41-copd-12-2059]--[@b43-copd-12-2059] Moreover, our data may support other psychosocial potential aspects useful for understanding and consequently enhancing patients' engagement in updated COPD management.[@b43-copd-12-2059]

Independently from clinical variables, patients' adherence enhancement should focus both on psychological factors and disease perception. Up to now, few evidence-based studies have allowed the identification of adequate intervention tools to increase adherence in chronic diseases.[@b7-copd-12-2059],[@b44-copd-12-2059] Our data could therefore contribute to broaden the perspective on similar interventions.

Intervention on anxiety and depression should never be neglected since the following two objectives could be reached: firstly to improve the patient's emotional status and secondly to indirectly intervene on adherence self-management.

Given the multifaceted aspects of adherence and such a widespread presence of MCI in the COPD population, the rehabilitative project should be personalized and tailored to individual needs.[@b45-copd-12-2059]

Cognitive behavioral therapy or psychological interventions could be implemented[@b37-copd-12-2059],[@b46-copd-12-2059] in the single-case situations where the presence of psychological difficulties could interfere with disease self-management, pulmonary rehabilitation adherence and outcome.

Finally, a self-report tool enabling heath workers to assess both pharmacological and nonpharmacological adherence, such as ASiCOLD, may allow them to focus on these aspects with indisputable advantages for a patient-centered and personalized pulmonary rehabilitative intervention for COPD patients. Further studies on this topic are much needed.

Conclusion
==========

Stemming from our experience and from literature, we think that pulmonary rehabilitation treatment, which integrates an interdisciplinary approach, a pharmacological/nonpharmacological management and a tailored intervention, could optimize the therapeutic approach in COPD patients without neglecting their clinical, relational and psychosocial needs.[@b4-copd-12-2059],[@b8-copd-12-2059],[@b9-copd-12-2059],[@b38-copd-12-2059],[@b45-copd-12-2059],[@b47-copd-12-2059],[@b48-copd-12-2059]

Supplementary material
======================

**Appendix A** Adherence Schedule in Chronic Obstructive Lung Disease-Revised
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These questions are about some of your ideas regarding your illness and treatment. There are no right or wrong answers. When responding, refer only to what you think about your illness and how you take care of yourself. Please put a cross by the answer you want to give.

  Questions                                                                                 Answers                               
  ----------------------------------------------------------------------------------------- ------------ ----------------- ------ -----------
  1\. Do you accept your disease?                                                           Not at all   A little Enough   Much   Very much
  2\. Do you accept the limitation related to your disease?                                 Not at all   A little Enough   Much   Very much
  3\. Does your family help you manage your disease?                                        Not at all   A little Enough   Much   Very much
  4\. Do your friends and/or other people you know help you manage your disease?            Not at all   A little Enough   Much   Very much
  5\. Do you ever forget to take your medicines?                                            Not at all   A little Enough   Much   Very much
  6\. Do you ever change the time you take your medicines?                                  Not at all   A little Enough   Much   Very much
  7\. Do you ever change your treatment according to how you feel?                          Not at all   A little Enough   Much   Very much
  8\. Do you ever change oxygen therapy prescriptions (amount and timing)? (If pertinent)   Not at all   A little Enough   Much   Very much
  9\. When you are at home, do you manage to follow the diet suggested to you?              Not at all   A little Enough   Much   Very much
  10\. When you are at home, do you manage to avoid smoking? (If pertinent)                 Not at all   A little Enough   Much   Very much
  11\. When you are at home, do you manage to exercise at least three times a week?         Not at all   A little Enough   Much   Very much

**Note:** Data from Majani et al.[@b49-copd-12-2059]

The study was funded by Clinical Scientific Institute Maugeri, IRCCS (ricerca corrente 2013).
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![Significant relations between clinical variables, psychological/neuropsychological factors, nonpharmacological adherence and disease perception.\
**Abbreviations:** 6MWT, 6-minute walking test; BMI, body mass index; MCI, mild cognitive impairment; DA, disease acceptance; DLA, disease limitations acceptance.](copd-12-2059Fig1){#f1-copd-12-2059}

###### 

Psychosocial and clinical characteristics of the study sample (n=84)

                                           n (%)
  ---------------------------------------- -----------
  Sex                                      
   Male                                    63 (75.0)
   Female                                  21 (25.0)
  Education (school years)                 
   ≤5                                      30 (35.7)
   6--8                                    37 (44.0)
   9--13                                   16 (19.1)
   ≥14                                     1 (1.2)
  Lives alone                              
   No                                      66 (78.6)
   Yes                                     18 (21.4)
  Marital status                           
   Married/common-law partner              46 (54.8)
   Widower                                 15 (17.9)
   Unmarried                               12 (14.3)
   Separated/divorced                      11 (13.0)
  Current occupation                       
   Retired                                 79 (94.1)
   Employed                                5 (5.9)
  Primary caregiver                        
   Nobody                                  38 (45.2)
   Husband/wife/partner                    21 (25.0)
   Daughter/son                            19 (22.6)
   Other family member/carer               6 (7.2)
  Smoker                                   
   No                                      6 (7.1)
   Yes                                     13 (15.5)
   Ex-smoker                               65 (77.4)
  COPD -- severity (GOLD)                  
   I-Low (FEV~1~/FVC \<70%, FEV~1~ ≥80%)   0
   II-Moderate (50%≤ FEV~1~ \<70%)         28 (33.3)
   III-Severe (30%≤ FEV~1~ \<50%)          31 (36.9)
   IV-Very severe (FEV~1~ \<30%)           25 (29.8)
  LTOT                                     
   No                                      26 (31.0)
   Yes                                     58 (69.0)

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; LTOT, long-term oxygen therapy.

###### 

Clinical characteristics of the study sample (n=84)

                      Mean    SD
  ------------------- ------- -------
  Age (years)         70.2    7.0
  Months of illness   105.1   81.5
  6MWT (minutes)      334.5   118.5
  BMI (kg/m^2^)       26.0    6.7
  FEV~1~ (L)          1.1     0.5
  FEV~1~%             44.2    18.6
  FVC (L)             2.4     0.8
  FVC%                76.3    20.5
  FEV~1~/FVC          45.7    12.8

**Abbreviations:** 6MWT, 6-minute walking test; BMI, body mass index; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity.

###### 

Psychological and neuropsychological characteristics of the study sample (n=84)

                                                                  n (%)
  --------------------------------------------------------------- -----------
  Anxiety symptoms (HADS-A)                                       
   None (0--7)                                                    50 (59.5)
   Mild (8--10)                                                   20 (23.8)
   Moderate (11--14)                                              11 (13.1)
   Severe (15--21)                                                3 (3.6)
  Depressive symptoms (BDI-II/GDS)                                
   None                                                           44 (53.3)
   Mild                                                           14 (16.9)
   Moderate                                                       13 (15.5)
   Severe                                                         12 (14.3)
  Cognitive deterioration (MMSE)                                  
   18.3≥×≤23.8                                                    3 (3.6)
   \>23.8                                                         81 (96.4)
  MCI (MoCA -- ES[\*](#tfn3-copd-12-2059){ref-type="table-fn"})   
   0                                                              8 (9.5)
   1                                                              13 (15.5)
   2                                                              17 (20.2)
   3                                                              14 (16.7)
   4                                                              32 (38.1)

**Notes:**

ES correspond to a five-point interval scale divided as follows: 0 indicates a performance to the worst 5% of the population; 4 indicates scores higher than the median value of the whole sample; 1, 2 and 3 are obtained by dividing into three equal parts the area of the distribution between 0 and 4 (37).

**Abbreviations:** HADS-A, Hospital Anxiety and Depression Scale-Anxiety; BDI-II, Beck Depression Inventory-second edition; GDS, Geriatric Depression Scale; MMSE, Mini Mental State Examination; MCI, Mild Cognitive Impairment; MoCA, Montreal Cognitive Assessment; ES, equivalent scores.

###### 

ASiCOLD-R: item score frequencies and percentage (n=84)

  ASiCOLD-R -- items                                Low n (%)   Moderate/high n (%)
  ------------------------------------------------- ----------- ---------------------
  Disease perception                                            
   Disease acceptance                               26 (30.9)   58 (69.1)
   Disease limitations acceptance                   24 (28.6)   60 (71.4)
   Perceived family support in disease management   9 (10.0)    73 (89.0)
   Perceived social support in disease management   39 (46.0)   44 (53.0)
  Self-efficacy                                                 
   Autonomous LTOT modifications (LTOT, n=58)       51 (87.9)   7 (12.1)
   Following dietary prescriptions                  20 (24.1)   63 (75.9)
   Avoiding smoking (smoking, n=16)                 9 (56.2)    7 (43.3)
   Exercising following medical advice              43 (51.8)   40 (48.2)

**Abbreviations:** ASiCOLD-R, Adherence Schedule in Chronic Obstructive Lung Disease -- Revised; LTOT, long-term oxygen therapy.
